C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.290
-0.130 (-5.37%)
At close: Jul 24, 2025, 4:00 PM
2.340
+0.050 (2.18%)
After-hours: Jul 24, 2025, 7:53 PM EDT
C4 Therapeutics Stock Forecast
CCCC's stock price has decreased by -64.66% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover C4 Therapeutics stock have a consensus rating of "Buy" and an average price target of $12, which forecasts a 424.02% increase in the stock price over the next year. The lowest target is $4 and the highest is $20.
Price Target: $12 (+424.02%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 19, 2024.
Analyst Ratings
The average analyst rating for C4 Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $8 → $12 | Hold → Buy | Upgrades | $8 → $12 | +424.02% | Dec 19, 2024 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $4 | Hold | Initiates | $4 | +74.67% | Nov 18, 2024 |
| BMO Capital | BMO Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +773.36% | Aug 6, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +249.34% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +511.35% | May 9, 2024 |
Financial Forecast
Revenue This Year
25.91M
from 35.58M
Decreased by -27.20%
Revenue Next Year
25.85M
from 25.91M
Decreased by -0.23%
EPS This Year
-1.77
from -1.52
EPS Next Year
-1.67
from -1.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.1M | 42.0M | 36.8M | ||
| Avg | 25.9M | 25.8M | 24.6M | ||
| Low | 16.4M | 16.7M | 10.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.1% | 62.1% | 42.2% | ||
| Avg | -27.2% | -0.2% | -4.9% | ||
| Low | -53.9% | -35.7% | -59.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.58 | -0.84 | -0.64 | ||
| Avg | -1.77 | -1.67 | -1.33 | ||
| Low | -2.35 | -2.44 | -2.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.